TEAD2 and neoplasm: Upon doxycycline addition, TEAD2-DN expression resulted in 66% inhibition of tumor cell growth in vitro, 96 h post doxycycline induction, Fig. 1A-B, accompanied by the downregulation of target genes CYR61 and CTGF, Fig. 1C, two frequently used and direct biomarkers of YAP1-TEAD activity [35–37].